The secondary analysis of an RCT reported by Probst (2023) demonstrated strong evidence for the effectiveness of a GLP-1 RA in reducing alcohol use in active alcohol drinkers with obesity - with a medium-to-large effect size to reduce alcohol use compared to a placebo after 12 weeks. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.